8.7 | | Gzme | 'clear cell sarcoma; TATCre' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
7 | | Gzme | 'acute graft vs. host disease; T-cell depleted bone marrow + T cells transplant' vs 'normal; T-cell depleted bone marrow transplant' | disease, stimulus | RNA-Seq of lymph node fibroblastic reticular cells isolated from bone marrow transplant recipient mice with or without acute Graft-versus-host disease on day 7 or untransplanted control mice |
6.4 | | Gzme | 'Salmonella enterica serovar Typhimurium' vs 'control' in 'bone marrow macrophage from 129P2 mouse strain' | clinical information, infect | Gene expression profiles of mouse embryonic stem cell derived macrophages infected with Salmonella typhimurium |
-6 | | Gzme | '6 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn0' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-6 | | Gzme | '3 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn0' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-5.9 | | Gzme | '6 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-5.9 | | Gzme | '3 day; osteogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
5.9 | | Gzme | 'bronchoalveolar adenocarcinoma induced using doxycycline' vs 'normal' | disease | Transcription profiling by array of lung alveolar type II epithelial cells with bronchoalveolar adenocarcinoma |
-5.2 | | Gzme | '6 day; myogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn0' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-4.8 | | Gzme | 'induced neural stem cell' vs 'mouse embryonic fibroblast cell' | cell type | Gene expression profile of mouse induced neural stem cells |
-4.7 | | Gzme | '3 day; myogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn0' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-4.7 | | Gzme | '6 day; myogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
3.9 | | Gzme | 'glioma' vs 'normal' | disease | Gene expression profile between glioma associated macrophages and normal brain tissue associated macrophages |
3.8 | | Gzme | 'clear cell sarcoma; Rosa26CreER' vs 'control' | disease, genotype | Mouse Model of Clear Cell Sarcoma |
3.6 | | Gzme | 'Kit ligand' vs 'none' in 'wasp knockout' | compound, genotype | Transcription profiling of bone marrow–derived mast cells from WASP-deficient mice after stimulation with kit ligand |
-3.4 | | Gzme | '3 day; myogenesis differentiation' vs ' 0 day; control' in '2C12-pMirn378' | cell line, growth condition, time | Effect of Mirn378 overexpression on gene expression during C2C12 myogenic and BMP2-induced osteogenic differentiation |
-3.3 | | Gzme | 'induced extraembryonic endoderm stem cell; grown in XEN cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
-3.1 | | Gzme | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'SWR/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
-3 | | Gzme | 'induced extraembryonic endoderm stem cell; grown in ES cell medium' vs 'mouse embryonic fibroblast; control' | cell type, growth condition | OSKM induce extraembryonic endoderm stem (iXEN) cells in parallel to iPS cells |
-2.8 | | Gzme | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'F1.B6x129' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
2.6 | | Gzme | 'etoposide; 2.5 micromolar' vs 'none' in 'H2afj-∆7-KO' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
-2.6 | | Gzme | 'ATF5 knockdown' vs 'wild type' in 'DMSO' | compound, genotype | Microarray to find ATF5 dependent genes in response to proteasome inhibition |
2.5 | | Gzme | 'etoposide; 2.5 micromolar' vs 'none' in 'wild type genotype' | compound, genotype | RNA-seq of H2afj-ko and isogenic WT C57/Bl6-N mouse embryonic fibroblasts in proliferation and after etoposide-induced senescence. |
2.5 | | Gzme | '5-aza-2'-deoxycytidine; 5 micromolar' vs 'none' | compound | Transcription profiling by array of mouse primary dermal fibroblasts after treatment with 5-aza-2'-deoxycytidine |
-2.5 | | Gzme | 'osteoblast culture 27 day' vs '0 day' | time | Transcription profiling by array of mouse primary neonatal osteoblasts to study the regulation of bone mineralisation |
2.5 | | Gzme | 'wormy, worm separated; Trichuris muris' vs 'control; non wormy' in 'caecum' | environmental stress, infect, organism part | RNA-seq of mouse intestinal mucosa to investigate infection by the parasitic nematode Trichuris muris |
2.4 | | Gzme | 'Kit ligand' vs 'none' in 'wild type' | compound, genotype | Transcription profiling of bone marrow–derived mast cells from WASP-deficient mice after stimulation with kit ligand |
-2.3 | | Gzme | 'osteoblast culture 9 day' vs '0 day' | time | Transcription profiling by array of mouse primary neonatal osteoblasts to study the regulation of bone mineralisation |
2.1 | | Gzme | 'transgenic C3(1)-SV40Tag; 20 week' vs 'wild type; 8 week' | age, genotype | Prevention of mammary tumor progression by silencing HoxA1 via intraductal injection of nanoparticle-formulated siRNA |
-2.1 | | Gzme | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'A/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
-2 | | Gzme | '19BL; differentiated 3factor-reprogrammed induced pluripotent stem cell' vs 'R1; differentiated embryonic stem cell' at '11 day' | cell line, growth condition, time | Natural cardiogenesis-based template predicts cardiogenic potential of induced pluripotent stem cell lines |
-2 | | Gzme | 'doxycycline-induced inactivation of ErbB3' vs 'ErbB3 expression' | phenotype | Transcription profiling by array of mouse mammary epithelial organoids after doxycyline-induced repression of ErbB3 expression |
1.8 | | Gzme | 'interleukin-3 and interleukin-33' vs 'interleukin-3' | growth condition | Stem cell factor programs the mast cell activation phenotype |
1.7 | | Gzme | 'SERF2-/-' vs 'SERF2+/+' | genotype | RNA-seq of mouse embryonic fibroblasts(MEFs) with knock-out of SERF2 compared to control MEFs |
1.7 | | Gzme | 'Foxd3 knockout' vs 'control' | phenotype | Expression data from embryonic stem cells differentiation |
1.6 | | Gzme | 'AZD8835; 50 milligram per kilogram' vs 'none' at '14 day' | compound, time | RNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835) |
-1.6 | | Gzme | '5-azacytidine 10 micromolar' vs 'none' | compound | Transcription profiling by array of mouse C2C12 cells treated with 5-azacytidine |
1.6 | | Gzme | 'Cebpg-/-' vs 'wild type' | genotype | Whole genome expression data comparison between WT and Cebpg-/- MEFs. |
-1.5 | | Gzme | 'mutant MyoD expression' at '24 hour' vs 'wild type MyoD expression' at '0 hour' | phenotype, time | Transcription profiling of mouse embryoic fibroblasts expressing wild type MyoD or its non-acetylatable version MyoD RRR to investigate how MyoD acetylation may contribute to differential gene activation. |
-1.5 | | Gzme | 'none; XPF knockout' vs 'all-trans-retinoic acid; 10 micromolar; wild type genotype' | compound, genotype | RNA-seq of mouse DNA repair endonuclease XPF knock out versus wild type and versus trans retinoic acid (tRA) treated wild type |
1.5 | | Gzme | 'AZD8835; 50 milligram per kilogram' vs 'none' at '7 day' | compound, time | RNAseq of tumor samples from CT26 syngeneic mouse treated with a PI3Ka/d inhibitor (AZD8835) |
-1.5 | | Gzme | 'STAT5 double knocked in' vs 'wild type' in 'interleukin-2' at '17 hour' | compound, genotype, time | Gene expression profile of splenic T cells from STAT5 double knocked in mice treated with IL-2 |
1.4 | | Gzme | 'CDK4/6 inhibitor PD 0332991' vs 'vehicle' | compound | Gene expression profile of mouse breast cancer V720 cells treated with vehicle or PD 0332991 |
1.4 | | Gzme | 'Kras G12D' vs 'wild type' | genotype | Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated Pdl1 Expression: Epithelial Cells |
-1.4 | | Gzme | 'STAT5 double knocked in' vs 'wild type' in 'interleukin-2' at '6 hour' | compound, genotype, time | Gene expression profile of splenic T cells from STAT5 double knocked in mice treated with IL-2 |
1.4 | | Gzme | 'Sall4 homozygous knockout' vs 'wild type genotype' | genotype | RNA-Seq of Sall4 mutants in mouse embryonic stem cells |
1.3 | | Gzme | 'Kit ligand; wasp knockout' vs 'Kit ligand; wild type' | compound, genotype | Transcription profiling of bone marrow–derived mast cells from WASP-deficient mice after stimulation with kit ligand |
-1.3 | | Gzme | 'mutant MyoD expression' at '12 hour' vs 'wild type MyoD expression' at '0 hour' | phenotype, time | Transcription profiling of mouse embryoic fibroblasts expressing wild type MyoD or its non-acetylatable version MyoD RRR to investigate how MyoD acetylation may contribute to differential gene activation. |
-1.2 | | Gzme | 'mutant MyoD expression' at '6 hour' vs 'wild type MyoD expression' at '0 hour' | phenotype, time | Transcription profiling of mouse embryoic fibroblasts expressing wild type MyoD or its non-acetylatable version MyoD RRR to investigate how MyoD acetylation may contribute to differential gene activation. |
1.2 | | Gzme | 'anti-mPDL1; anti-mCTLA4; 10 milligram per kilogram' vs 'none' at '7 day' | compound, time | RNAseq of tumor samples from CT26 syngeneic mouse treated with a PD-L1 and CTLA-4 immunotherapy combination |
-1.2 | | Gzme | 'total RNA; HRasV12 and c-Myc overexpression and Eif4e wild type' vs 'total RNA; wild type' | fraction, genotype | Redefining the role of eIF4E dose in development, cancer, and protein synthesis |
1.1 | | Gzme | 'Mycobacterium tuberculosis H37Rv' vs 'none' in 'TNF-alpha knockout' | compound, genotype, infect | 4-week mouse comparative study on effect of neutralizing IL-17A, IL-17F and TNFa antibodies |
-1.1 | | Gzme | 'MG132; 1 micromolar' vs 'DMSO' in 'wild type' | compound, genotype | Microarray to find ATF5 dependent genes in response to proteasome inhibition |
1.1 | | Gzme | 'IRAK1BP1 KO' vs 'wild type' in 'none' | genotype, treatment | Identification of TNFα-induced genes that are IRAK1BP1 dependent |
1.1 | | Gzme | 'glioblastoma multiforme' vs 'normal' | disease | Analysis of the expression profiles of glioma-associated microglia/macrophages and naive control cells in Mus musculus. |
-1.1 | | Gzme | 'STAT5 double knocked in' vs 'wild type' in 'interleukin-2' at '2 hour' | compound, genotype, time | Gene expression profile of splenic T cells from STAT5 double knocked in mice treated with IL-2 |
1 | | Gzme | 'IRAK1BP1 KO' vs 'wild type' in 'TNFα' | genotype, treatment | Identification of TNFα-induced genes that are IRAK1BP1 dependent |
1 | | Gzme | 'parathyroid hormone; 10 nanomolar' vs 'none' in 'wild type' | compound, genotype | Transcription profiling by array of mouse primary osteoblastic cells from arrb2 knockout treated with parathyroid hormone |